Código QR (código de barras bidimensional)

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently, mainly driven by MAPK pathway bypass, secondary R...

ver descrição completa

Na minha lista:
Principais autores: Caio Abner Leite, Raíssa Pierri Carvalho, Felipe Marques da Costa, Augusto Kreling Medeiros, Fabio Augusto Schutz, William Nassib William
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2023-10-01
coleção:Frontiers in Oncology
Assuntos:
lung adenocarcinoma
RET fusion
MET amplification
selpercatinib
capmatinib
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2023.1264231/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados